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Androgen receptor deﬁcient miceAndrogen reduces fat mass, although the underlying mechanisms are unknown. Here, we examined
the effect of testosterone on heat production and mitochondrial biogenesis. Testosterone-treated
mice exhibited elevated heat production. Treatment with testosterone increased the expression
level of peroxisome proliferator-activated receptor-c coactivator-1a (PGC1a), ATP5B and Cox4 in
skeletal muscle, but not that in brown adipose tissue and liver. mRNA levels of genes involved in
mitochondrial biogenesis were elevated in skeletal muscle isolated from testosterone-treated male
mice, but were down-regulated in androgen receptor deﬁcient mice. These results demonstrated
that the testosterone-induced increase in energy expenditure is derived from elevated mitochon-
drial biogenesis in skeletal muscle.
 2014 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Testosterone deﬁciency leads to increased fat mass and insulin
resistance [1]. Epidemiological studies demonstrate that low tes-
tosterone level is associated with type 2 diabetes and metabolic
syndrome [2,3]. A double-blind placebo-controlled study reveals
that testosterone replacement therapy reduces HOMA index, fast-
ing glucose, HbA1c and waist circumference in type 2 diabetic pa-
tients with hypogonadism [4]. Our previous study demonstrated
that treatment with dehydroepiandrosterone (DHEA) and
testosterone equally reduces adiposity in rats [5]. Both DHEA and
testosterone equally suppress 3T3-L1 preadipocyte proliferation
and expression of PPARc in 3T3-L1 adipocytes. In this study, we
found that these effects of DHEA are mediated via the androgen
receptor (AR). However, the mechanism of weight reduction is un-
clear. Since neither DHEA nor testosterone suppresses food con-
sumption, we hypothesized that they may increase energy
expenditure. This prompted us to examine the effect of treatmentwith testosterone on oxygen consumption. As we found that an in-
crease in serum testosterone level enhances heat production with-
out increasing locomotor activity, we investigated the effect of
testosterone on mitochondrial biogenesis and the expression of
its key regulator, peroxisome proliferator-activated receptor-c
coactivator-1a (PGC1a).2. Materials and methods
2.1. Animals
C57/Black male mice at 8 weeks of age were fed CE2 powder
with (testosterone group) or without (control group) 0.4% testos-
terone ad libitum for 4 weeks. They were housed in a speciﬁc path-
ogen-free facility with a 12-h light/12-h dark cycle. Androgen
receptor deﬁcient mice (ARKO) were established with Cre-lox sys-
tem as described previously [6,7]. They were fed CE2 ad libitum.
After the treatment with testosterone, the animals were decapi-
tated to collect epididymal fat (WAT), brown adipose tissue
(BAT), liver and gastrocnemius muscle. In addition, these organs
were harvested at 8 and 25 weeks of age in ARKO.
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Animal Care Committee.
2.2. Measurement of oxygen consumption and locomotor activity
O2 consumption, CO2 production and locomotor activity were
measured by indirect calorimetry as described previously [8].
2.3. Cell culture
C2C12 myoblasts were cultured in DMEM supplemented with
10% fetal bovine serum, 100 U/mL penicillin, and 0.1 mg/mL strep-
tomycin. Cells were incubated at 37 C in a humid atmosphere of
5% CO2 in air. When cells reached 90% conﬂuence, the medium
was exchanged for DMEM containing 4% horse serum (differentia-
tion medium). After the incubation with differentiation medium
for 7 days, cells were morphologically determined to differentiate
C2C12 myotubes. C2C12 myotubes were treated with various con-
centrations (0, 1, 10 and 100 nM) of testosterone for 48 h.
2.4. Assay for serum testosterone concentration
Serum testosterone concentration was measured with DPC
Total Testosterone Kit (Diagnostic Products Corporation).0 
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Fig. 1. Body weight, fat weight, plasma glucose level in testosterone-treated mice and
4 weeks. Body weight in control (white) and treated (black) mice (n = 16, ⁄: P < 0.05 contr
(closed square-solid line) mice (n = 16, ⁄: P < 0.05 control vs treated). (C) Serum testos
Epididymal fat weight in control and treated mice (n = 16, ⁄: P < 0.05 control vs treated
treated). (F) Calculated heat production in control (white) and treated (black) mice duri
treated). (G) Locomotor activity in control (white) and treated (black) mice during light p
(H) Body weight in wild type and ARKOmice at 24 weeks of age (n = 3, ⁄: P < 0.05 wild typ
(n = 3, ⁄: P < 0.05 wild type vs ARKO). (J) Plasma glucose levels in wild type and ARKO (n
ARKO (n = 3, ⁄: P < 0.05 wild type vs ARKO).2.5. Real time PCR
Total RNA from gastrocnemius muscle isolated from mice trea-
ted with testosterone and ARKO, and C2C12 myotubes were ex-
tracted using TRIzol, and puriﬁed as described previously [9].
Reverse transcription was performed using a PrimeScript Reverse
Transcriptase (TAKARA) genes were established using SYBR Premix
Ex Taq Kit (TAKARA) according to the manufacturer’s instructions.
20 ll of the reaction solution consisted of 2 ll of the template,
10 ll of SYBR Premix Ex Taq, 0.4 ll of 10 lM of each primer and
0.4 ll of ROX Reference Dye. PCR ampliﬁcation was performed as
follows: predenaturation for 1 cycle at 95 C for 30 s, and 40 cycles
at 95 C for 5 s, 60–62 C for 30 s using a Thermal Cycler Dice
(TAKARA, Ohtsu, Japan). Expression levels, calculated as copy num-
bers in each sample, were normalized to the expression level of
GAPDH. Oligonucleotide primers were designed, based on se-
quences from the GeneBank database (Supplemental Table).
2.6. Quantiﬁcation of mitochondrial DNA (mitDNA)
Total DNA containing nuclear DNA and mitDNA was extracted
using ZymoBead™ Genomic DNA kit (Zymo Research Corp, Irvine,
CA). Real time PCR was performed as described above to quantify
mitDNA (16S rRNA: CCGCAAGGGAAAGATGAAAGAC (f) and TCGTT0 
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ARKO. (A) C57/black mice were treated with food containing 0.4% testosterone for
ol vs treated). (B) Food consumption in control (open circle-dotted line) and treated
terone level in control and treated mice (n = 8, ⁄⁄: P < 0.01 control vs treated). (D)
). (E) Fasting plasma level in control and treated mice (n = 8, ⁄: P < 0.05 control vs
ng light phase (12 h), dark phase (12 h) and total (24 h) (n = 7, ⁄: P < 0.05 control vs
hase (12 h), dark phase (12 h) and total (24 h) (n = 7, ⁄: P < 0.05 control vs treated).
e vs ARKO). (I) Epididymal fat weight in wild type and ARKO mice at 24 weeks of age
= 3, ⁄: P < 0.05 wild type vs ARKO). (K) Serum testosterone levels in wild type and
T. Usui et al. / FEBS Letters 588 (2014) 1935–1941 1937TGGTTTCGGGGTTTC (r)) and nuclear DNA (cyclophilin A: TTCCTCC
TTTCACAGAATTATTCCA (f) and CCGCCAGTGCCATTATGG (r))
simultaneously in 10–10000 times diluted total DNA. The copy
number of mitDNA was normalized with nuclear DNA. We assayed
the amount of mitDNA in skeletal muscle isolated from C57/Black
male mice treated with or without testosterone for 4 weeks as de-
scribed above.
2.7. Western blotting
Gastrocnemius muscle, WAT, liver and BAT were homogenized
in RIPA buffer (Sigma Aldrich, St. Louis MO). Cell lysates were
mixed with Laemmli sample buffer and boiled for 3 min. Equal
amounts of cell lysate were subjected to SDS–PAGE, and trans-
ferred onto nitrocellulose paper. The paper was blocked with 5%
skim milk TBS, and incubated with anti-PGC1 antibody (Santa Cruz
Biotech, Santa Cruz, CA), anti-ATP5B antibody (Aviva Systems Biol-
ogy, San Diego, CA), anti-Cox4 antibody (Gene Tex, Irvine, CA) or
anti-cytochrome C antibody (Gene Tex, Irvine, CA). Protein bands
were visualized with an ECL system.
2.8. Immunohistochemical staining
Mitochondria staining of parafﬁn sections of each tissue was
carried out using anti-ATP5B antibody (Aviva Systems Biology,Muscle
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Fig. 2. Expression levels of PGC1a and mitochondrial protein in various organs isolated
expression levels in muscle, BAT and liver isolated from control and treated mice. (B–D
(white) and testosterone-treated (black) mice (n = 8, ⁄⁄: P < 0.01, control vs treated mice).
and ARKO (gray) mice (n = 3, ⁄: P < 0.05, wild type vs ARKO).San Diego, CA, USA), and Vectastain ABC kit (Vector Laboratories,
Burlingame, CA, USA).
2.9. Statistics
Statistical comparisons were performed with Student t-test
(Figs. 1C–K and 3B–F) one-factor ANOVA (Figs. 2B–F and 1A–H).
All statistical tests were two-tailed. Data are given as mean ± S.E.M.
Values of P < 0.05 were considered statistically signiﬁcant.3. Results
3.1. Effect of treatment with testosterone on body weight, food
consumption, and plasma glucose in male C57Black mice and ARKO
Treatment food containing 0.4% testosterone suppressed the
body weight gain, despite no signiﬁcant decrease in food consump-
tion being observed except during the ﬁrst week (Fig. 1A and B).
Serum testosterone level was elevated up to approximately 12-fold
in the testosterone group (Fig. 1C), which was accompanied with
decreases in epididymal fat weight and fasting plasma glucose
level (Fig. 1D and E). These results indicated that testosterone-
induced weight loss is not fully explained by decreased food con-
sumption alone.B
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from testosterone-treated mice and ARKO. (A) Western blot showing the PGC 1a
) Quantiﬁed value of PGC1a (B), ATP5B (C) and Cox4 (D) protein levels in control
(E, F) Quantiﬁed value of PGC1a (E) and ATP5B (F) protein levels in wild type (white)
1938 T. Usui et al. / FEBS Letters 588 (2014) 1935–1941Heat production during 24 h and the light (resting) phase was
elevated up to 114% and 124%, respectively (Fig. 1F), whereas loco-
motor activity in 24 h and the dark phase was suppressed in the
testosterone-treated mice (Fig. 1G). Respiratory quotient was not
inﬂuenced by treatment with testosterone.
Body weight and epididymal fat weight were increased in ARKO
at 25 weeks of age compared with their wild type littermates
(Fig. 1H and I), with no difference however observed in fasting plas-
ma glucose (Fig. 1J). Serum testosterone level was decreased in
ARKO at 25 weeks compared with wild type (Fig. 1K). No differ-
ences in body weight, fat weight or fasting plasma glucose level
were observed between ARKO and wild type at 8 weeks of age, as
described previously [6] (data not shown).
3.2. Effects of treatment with testosterone on mitochondrial biogenesis
Next, we evaluated the effect of testosterone on the expression
levels of PGC1a and mitochondrial biogenesis in skeletal muscle
(gastrocnemius muscle), liver, BAT and WAT. We observed ele-
vated protein levels of PGC1a only in skeletal muscle isolated from
testosterone-treated mice (Fig. 2A and B). In addition, treatment
with testosterone increased the expression of protein levels of
ATP5B and Cox4 in skeletal muscle (Fig. 2C and D). Conversely,
expression levels of PGC1a and ATP5B protein were suppressed
in skeletal muscle isolated from ARKO (Fig. 2E and F). TheFig. 3. Expression of genes involved in mitochondrial biogenesis in skeletal muscle. (A) Im
BAT isolated from control and testosterone-treated mice. (B) Expression of mRNA in skele
⁄: P < 0.05 control vs treated mice). (C) Amount of mitochondrial DNA (16S rRNA) adju
testosterone-treated mice (n = 5, ⁄: P < 0.05 control vs treated mice). (D) Expression of m
troponin C2 (Trop C2: type II muscle ﬁber) and troponin T3 (Trop T3: type II muscle ﬁbe
mice (n = 6, ⁄: P < 0.05 control vs treated mice). (E) Expression of mRNA in skeletal muscle
wild type vs ARKO). (F) Expression of myoglobin, troponin I1, troponin C2 and troponin T
P < 0.05, ⁄⁄: P < 0.01, wild type vs ARKO).expression levels of PGC1a, Cox4 and ATP5B tended to decrease
in skeletal muscle from ARKO, but not signiﬁcantly so (data not
shown). These results clearly imply that androgen increases
expression of PGC1a and subsequent mitochondrial biogenesis
exclusively in skeletal muscle.
Immunohistochemical study revealed that treatment with tes-
tosterone up-regulated the expression of mitochondrial Cox4 in
skeletal muscle but not BAT (Fig. 3A). To conﬁrm that mitochon-
drial biogenesis is elevated by treatment with testosterone in
skeletal muscle, mRNA expression of genes involved in mitochon-
drial biogenesis including PGC1a, NRF-1, NRF-2 and Tfam was
evaluated. As shown in Fig. 3B, mRNA levels of these genes were
increased in testosterone-treated mice. Moreover, mitDNA
(Fig. 3C) was elevated by treatment with testosterone. PGC1a con-
verts muscle ﬁbers from type II (fast twitch with abundant tropo-
nin T3 and troponin C2) to type I (slow twitch with abundant
myoglobin and toponin I1) [10–12]. The expression levels of myo-
globin and troponin I were increased in the testosterone-treated
mice (Fig. 3D), which suggested that conversion of muscle ﬁbers
might be induced by testosterone. On the other hand, mRNA levels
of these genes were reduced in skeletal muscle of ARKO (Fig. 3E).
Furthermore, the ratio of myoglobin/troponin I was decreased
in ARKO (Fig. 3F). These data indicated that treatment with
testosterone increases the expression level of PGC1a, which leads
to elevated mitochondrial biogenesis in skeletal muscle.munohistochemical study exhibiting the expression of Cox4 in skeletal muscle and
tal muscle isolated from control (white) and testosterone-treated (black) mice (n = 6,
sted by nuclear DNA (cyclophilin A) in skeletal muscle isolated from control and
yoglobin (Myo: type I muscle ﬁber) and troponin I1 (Trop I1: type I muscle ﬁber),
r) in skeletal muscle isolated from control (white) and testosterone-treated (black)
isolated from wild type (white) and ARKO (gray) mice (n = 3 ⁄: P < 0.05, ⁄⁄: P < 0.01,
3 in skeletal muscle isolated from wild type (white) and ARKO (gray) mice (n = 3 ⁄:
T. Usui et al. / FEBS Letters 588 (2014) 1935–1941 19393.3. Effect of treatment with testosterone on mitochondrial biogenesis
in C2C12 myotubes
We examined the effect of treatment with various concentra-
tions of testosterone for 48 h on mitochondrial biogenesis in
C2C12 myotubes. 10 nM testosterone signiﬁcantly increased mRNA
levels of genes related to mitochondrial biogenesis including
PGC1a, NRF1, NRF2 and Tfam, as well as mitochondrial gene, cyto-
chrome C (Fig. 4A–E). Testosterone-induced up-regulation of
PGC1a and cytochorome Cwas abolished by the androgen receptor
antagonist, ﬂutamide, but not the estrogen receptor antagonist,
fulvestrant (Fig. 4F and G). These results indicate that testosterone
at physiological concentrations is effective in promoting mitochon-
drial biogenesis. In addition, the androgen receptor antagonist, ﬂu-
tamide, completely abolished the testosterone-induced elevations
of PGC1a and cytochrome C mRNA. As estrogen receptor antago-
nist, fulvestrant, failed to inﬂuence the testosterone-induced
mitochondrial biogenesis, these effects of testosterone must be
mediated via the androgen receptor.
4. Discussion
Various clinical evidence has demonstrated that hypogonadism
in men is frequently associated with type 2 diabetes [1]. Recent
investigations have shown that this is common in non-WesternTestosterone (nM) Testoster
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ﬂutamide, or 1 lM fulvestrant for 48 h. The expression levels of PGC1a (F) and cytochrocountries [13,14]. Moreover, hypogonadotropic hypogonadism oc-
curs commonly in type 2 diabetes [15]. Since testosterone is easily
converted to estradiol, a serum low testosterone level is not equal
to low androgen receptor activity. A study on ARKO demonstrated
clearly that late onset obesity is observed in these mice [6], which
implies that androgen signaling is required to prevent obesity in
men.
Here, we investigated the mechanism of testosterone-induced
weight reduction. Our previous study demonstrated that treatment
with both DHEA and testosterone reduced the expression levels of
PPARc, aP2 and lipoprotein lipase in 3T3-L1 adipocytes [5] and adi-
pose tissue [16]. Suppression of PPARc activity promotes leanness
in PPARc-deﬁcient mice [17] and Pro12Ala polymorphism in hu-
mans [18]. However, these hormones do not inﬂuence the gene
expression levels involved in triglyceride synthesis and lipolysis.
Since obesity is a state of pathological energy accumulation,
weight reduction should be explained by a decrease in energy in-
take and/or increase in energy expenditure. The present results
indicated that testosterone administration increases energy pro-
duction without signiﬁcant suppression of food intake. This result
is consistent with the fact that oxygen consumption is decreased
without an increase in food consumption in ARKO [6,19]. De-
creased locomotor activity in testosterone treated mice was unex-
pectedly shown, because lowered spontaneous activity was
observed in ARKO [19]. These results suggest that locomotorone (nM) Testosterone (nM) 
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drial biogenesis in C2C12 myotubes. (A–E) Fully differentiated C2C12 myotubes were
GC1a (A), NRF1 (B), NRF2 (C), Tfam (D) and cytochrome C (E) mRNA were measured
bes were incubated with (black) or without (white) 10 nM testosterone, and 1 lM
me C (G) mRNA were shown.
1940 T. Usui et al. / FEBS Letters 588 (2014) 1935–1941activity and androgen signal may not be correlated linearly.
Although we are unable to explain the underlying mechanism,
we speculate that it might be due to some testosterone-induced
action on the central nervous systems. In any case, the increase
in energy expenditure and resultant weight loss despite reduced
locomotor activity in testosterone-treated mice is derived from
an increased basal metabolic rate.
Next we examined mitochondrial biogenesis. PGC1a was iden-
tiﬁed as a stimulator of mitochondrial biogenesis in muscle cells
[20]. Recently, PGC1a is known to regulate mitochondria biogene-
sis in a tissue-speciﬁc manner [10]. The activity of PGC1a is regu-
lated on both the transcriptional level, such as PPAR family, cAMP
response element, mTOR, and post-transcriptional level, including
Akt, AMPK and Sirt1 [21]. Mitochondrial biogenesis requires very
complex processes. Expression of mitochondrial proteins encoded
in the nucleus is regulated by NRF1 and NFR2. Additionally, pro-
teins encoded in the mitDNA are under the control of Tfam, the
expression of which is regulated by NFR1 and NFR2 [22,23]. Our
data demonstrate clearly that treatment with testosterone results
in up-regulation of PGC1a and subsequent mitochondrial biogene-
sis in skeletal muscle. Moreover, we observed reduced expression
of PGC1a and mitochondrial biogenesis in skeletal muscle isolated
from ARKO. Although treatment with testosterone increased the
serum testosterone level up to more than 10-fold in vivo, testoster-
one at physiological concentrations is sufﬁcient to increase mito-
chondrial biogenesis in C2C12 myotubes. On the other hand,
ARKO exhibit the opposite phenotype to mice treated with testos-
terone. As shown in Fig. 1K, the circulating testosterone level is
suppressed in ARKO due to atrophic testis [24]. Since low testoster-
one concentration and blockade of AR lead to decreased mitochon-
drial biogenesis, as shown in Fig. 4F and G, we speculate that the
serum testosterone level and expression level of AR may exert an
equal inﬂuence on mitochondria biogenesis in muscle in ARKO.
As the estrogen receptor antagonist, fulvestrant, failed to inﬂuence
the testosterone-induced mitochondrial biogenesis, these effects of
testosterone must be mediated via the androgen receptor.
We indicate that testosterone-induced increased mitochondrial
biogenesis in skeletal muscle accounts for the testosterone-in-
duced increase in energy expenditure. Contrary to our expectation,
the mitochondrial biogenesis was not increased with treatment
with testosterone in BAT. As the expression of PCG1a is positively
regulated by activation of PPARc in adipocytes [23], testosterone-
induced reduction of PPARc [5] might attenuate the increase of
PGC1a in WAT and BAT. Actually, the effect of androgen on BAT
has been controversial. Treatment with testosterone suppressed
the expression of uncoupling protein 1 (UCP-1) [25] in cultured
BAT, whereas UCP-1 expression was severely reduced in ARKO
[17].
Our results indicate that skeletal muscle is a major organ con-
tributing to androgen-induced weight loss. Myocyte-speciﬁc ARKO
are reported to display lower body weight and visceral fat weight
than their wild type littermates [26]. Conversely, selective overex-
pression of AR in myocytes of wild type rats and in rats carrying
the testicular feminization mutation (a loss of functional AR in
the whole body) heve been reported to result in reduced adiposity,
increased O2 consumption and increased mitochondrial volume in
muscle [27,28]. Fernando et al. concluded that increased AR signal-
ing in myocytes is sufﬁcient to decrease fat volume [27]. These re-
sults are consistent with those of our study. However, their results
indicated that AR signaling increased the amount of fast twitch
myoﬁbers [28], which was not in agreement with our ﬁndings. Fur-
ther investigation of the molecular interaction between AR and
PGC1a will be needed to clarify these discrepancies.
In conclusion, our results demonstrated that testosterone-
induced reduced adiposity is associated with increased mitochon-
drial biogenesis in skeletal muscle.Acknowledgment
The authors thank Dr Shigeaki Kato for providing the ARKO.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.febslet.2014.03.
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